June #188 : PIs in First Trimester Linked to Premature Births - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

The Sound of Stigma

Artful Warriors

From the Editor

We Are Family

Feedback

Letters-June 2013

The POZ Q+A

Out of the Shadows

POZ Planet

Beyond the Pale

Koch vs. Koop

The New 'Normal'

Fountain of Youth

National HIV Coming Out Day?

To Be Continued

In the Beginning

R.I.P. NAPWA

Voices

Immigration Status

Care and Treatment

GMHC Treatment Issues June 2013

Generics Save Money but May Come With Risks

TasP Movement Gains Momentum

PIs in First Trimester Linked to Premature Births

Child 'Functionally Cured' of HIV?

Research Notes

Prevention: New Understanding of Old Vaccine

Treatment: CD4 Tests Needed Only Yearly?

Cure: Gene Therapy Has HIV in a Bind

Concerns: Health Threats Outside of AIDS

POZ Survey Says

The Doctor Is In

POZ Heroes

Trailblazer

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

June 2013

PIs in First Trimester Linked to Premature Births

by Benjamin Ryan

Pregnant women who use protease inhibitors (PIs) during their first trimester have a more than 50 percent increased risk of premature delivery, according to a recent paper from the Pediatric HIV/AIDS Cohort Study. Regimens with non-nucleoside reverse-transcriptase inhibitors or triple-nucleosides were not associated with preterm delivery in the study, nor was PI use in the second or third trimesters. Previous research on how PIs affect preterm birth has been mixed, with some agreeing with these latest conclusions but others finding no association.

“I think we need more data before we would recommend against use” of PIs to pregnant women, says the study’s principal investigator, Heather Watts, MD, a medical officer at the Eunice Kennedy Shriver National Institute of Child Health & Human Development in Rockville, Maryland.

Search: pregnancy, protease inhibitors, premature delivery, Pediatric HIV/AIDS Cohort Study

Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         

[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    chrisf
    san jose
    California


    mtaj0818
    Washington
    DC


    ernienyc
    Bronx
    New York


    RayOctober
    Richmond
    Virginia
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.